Login to Your Account



Biocardia pumped: FDA clears the way for phase III heart failure trial

By Randy Osborne
Staff Writer

Tuesday, November 11, 2014

Biocardia Inc. said the FDA has given its nod to start a phase III trial with CardiAMP, the firm's bone marrow-derived therapy for heart failure.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription